GuerbetCHIX:GBTP 66 EV-to-FCF is 9.09 as of Jul. 01, 2026, which is 15% below its 10-year median of 10.69. GuruFocus rates CHIX:GBTP with a GF Score™ of 66/100 and a GF Value™ of €66.22. The stock has 5 warning signs investors should review. Among 419 Medical Devices & Instruments companies, Guerbet ranks better than 84.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Guerbet's Enterprise Value is €404.5 Mil.
Guerbet's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €44.5 Mil. Therefore, Guerbet's EV-to-FCF for today is 9.09.
The historical rank and industry rank for Guerbet's EV-to-FCF or its related term are showing as below:
CHIX:GBTp'
s EV-to-FCF Range Over the Past 10 Years
Min: -123.8 Med: 10.69 Max: 229.04
Current: 9.05
During the past 13 years, the highest EV-to-FCF of Guerbet was 229.04. The lowest was -123.80. And the median was 10.69.
CHIX:GBTp's EV-to-FCF is ranked better than 84.01% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.57
vs CHIX:GBTp: 9.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-01), Guerbet's stock price is €30.025.
Guerbet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.910. Therefore, Guerbet's PE Ratio (TTM) for today is At Loss.
Guerbet (CHIX:GBTp) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guerbet's share price for today is €30.025.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Guerbet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guerbet EV-to-FCF Related Terms
Guerbet EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Guerbet's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Guerbet's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guerbet EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guerbet's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Guerbet's EV-to-FCF falls into.
Guerbet's current Enterprise Value is €404.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Guerbet's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €44.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guerbet (CHIX:GBTP) has a EV-to-FCF of 9.09 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guerbet and its competitors. This is 15% below median its historical median of 10.69. According to the industry distribution chart, Guerbet ranks #67 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 16%.
Is Guerbet's EV-to-FCF too high?
Guerbet's current EV-to-FCF of 9.09 is 15% below median its 10-year median of 10.69. The Medical Devices & Instruments industry median EV-to-FCF is 22.57. Guerbet's value of 9.09 is 59.7% below this industry median. Based on the distribution chart, Guerbet ranks #67 out of 419 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Guerbet has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Guerbet's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Guerbet ranks #67 out of 419 companies for EV-to-FCF. This places Guerbet in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 22.57. Guerbet's value of 9.09 is 59.7% below this benchmark. While the company's 10-year median is 10.69 vs. the industry median of 22.57, Guerbet has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.57, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guerbet's current EV-to-FCF of 9.09 is 59.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guerbet and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guerbet's current EV-to-FCF is 9.09, which is 15% below median its own 10-year median of 10.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guerbet stock overvalued right now?
Guerbet (CHIX:GBTP) has a current EV-to-FCF of 9.09. The stock's GF Value™ is €66.22, compared to a current price of €30.03 — trading 54.7% below its estimated fair value. The current EV-to-FCF is 9.09, which is 15% below median its 10-year median of 10.69 and 59.7% below the Medical Devices & Instruments industry median of 22.57. Guerbet's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guerbet (CHIX:GBTP), the current EV-to-FCF is 9.09 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guerbet (CHIX:GBTP) Overvalued in 2026?
Based on GuruFocus' analysis, Guerbet stock appears to be undervalued.
The current stock price of €30.03 is trading 54.7% below its estimated GF Value™ of €66.22.
Key valuation signals for CHIX:GBTP:
EV-to-FCF: 9.09 (15% below median its 10-year median of 10.69)
GF Value™: €66.22 vs. price of €30.03 (54.7% below fair value)
Industry Position: 59.7% below the Medical Devices & Instruments median (#67 of 419)
No single metric tells the full story. See the CHIX:GBTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
66GF Score
Get the complete analysis for CHIX:GBTP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GBTP has been successfully added to your 
